Trump aims to curb direct-to-consumer ads for drugs. Hims & Hers Health could be targeted.

Core Viewpoint - The Trump administration has introduced an executive action to restrict direct-to-consumer advertising for pharmaceuticals, responding to concerns raised by recent developments in the industry [1] Group 1: Executive Action Details - The executive action aims to limit the ability of pharmaceutical companies to advertise directly to consumers, which officials believe could lead to more informed healthcare decisions [1] - This move is part of a broader strategy to address rising drug prices and improve transparency in the pharmaceutical industry [1] Group 2: Industry Impact - The action is expected to have significant implications for companies engaged in direct-to-consumer marketing, particularly those like Hims & Hers Health, which have been prominent in this space [1] - Industry officials are concerned that such restrictions could hinder innovation and access to information for consumers [1]